SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ALE.P02 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New mRNA vaccine combo takes on tough lung cancer in phase 2 trial
Disease control Recruiting nowThis Phase 2 trial tests whether adding a personalized mRNA vaccine (V940) to standard pembrolizumab and chemotherapy helps people with newly diagnosed metastatic squamous non-small cell lung cancer live longer and keep the cancer from growing. About 180 participants will receive…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough cancers? early trial launches for ABBV-711
Disease control Recruiting nowThis early-phase study tests an experimental drug called ABBV-711, alone or with another drug (budigalimab), in adults with advanced squamous tumors (like certain lung or head and neck cancers). The main goals are to check safety and see if the tumors shrink. About 220 people wil…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for advanced cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug hopes to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill takes on tough cancers: early trial launches
Disease control Recruiting nowThis study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC